Hepatitis

Forecast: Hepatitis C drug market to hit $10 billion in 2013

Published in Hepatitis Weekly, May 17th, 2004

Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, has found the growing number of patients with advanced liver disease will fuel a rise of the hepatitis C virus (HCV) market to $10 billion in 2013.

HCV disease burden is expected to rise during the next 10 years because of a maturing HCV population that has been infected for more than 20 years, the amount of time it takes for morbidity from HCV to emerge.

The new Pharmacor study entitled "Hepatitis C Virus" also found experts disagree about which patients are best suited for treatment given that HCV does not place all infected persons at risk of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry